HIV INFECTION IN CHILDREN OF IV DRUG ABUSERS

Project: Research project

Description

The incidence of acquired immunodeficiency syndrome (AIDS) in
children is increasing, the source of infection usually being the
mother. Approximately 75% children with HIV infection are
offspring of IV drug abuser parent(s). Diagnosis of HIV infection
in newborns and asymptomatic infants is, however, a problem because
all infants born to HIV seropositive woemen have passively
transferred maternal antibodies which may persist up to and even
beyond 15 months of age. Infected and uninfected infants thus
cannot be distingushed on the basis of routine immunological or
serological testing. A hypothesis of this proposal is that HIV
infected infants have HIV-specific B & T cells whose properties can
be exploited in-vitro to enable the distrinction between infected
and uninfected infants. Novel tests of HIV-specific immunity (in-
vitro HIV antibody synthesis, antibody clonotype pattern and HIV
antigen specific lymphoproliferation) will be coupled with tests
for the polymerase chain reaction, HIV viral cultures and HIV
antigen in a multi-test diagnostic approach to this probolem. HIV infection in the pediatric population results in a wide
spectrum of clinical and immunologic distrubances, ranging from
asymptomatic to severely ill and form immunocompetent to severely
immunocompromised status. Main target systems attacked by HIV are
the immune system and the nervous system. A second hypothesis to
be tested is that rapidity of disease progression is closely linked
to initial clinical presentation and laboratory findings.
Systematic investigations of the neurological and immunological
status, HIV-specific immunity and HIV antigen levels will provide
insights into the clinical, virologic and immunologic spectrum in
this disease. An important feature of this investigation will be
data management. The ability of diagnosing HIV infection in
infancy and an understanding of the mechanisms involved in disease
progression should bring us closer to developing and monitoring
therapeutic strategies against this deadly disease.
StatusFinished
Effective start/end date4/1/893/31/01

Funding

  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $519,861.00
  • National Institutes of Health

Fingerprint

Drug Users
HIV Infections
HIV
Apoptosis
Cytokines
Immunity
Antibodies
HIV Antigens
T-Lymphocytes
Disease Progression
HIV Antibodies
Lymphocytes
Interleukin-2
Routine Diagnostic Tests
Nervous System
Up-Regulation
Tumor Necrosis Factor-alpha
Immune System
Acquired Immunodeficiency Syndrome
Lymphocyte Depletion

ASJC

  • Medicine(all)